Psychological Symptom Trajectories and Non–Small Cell Lung Cancer Survival: A Joint Model Analysis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective: Lung cancer remains the number one cause of cancer-related mortality worldwide, but less known is that lung cancer patients are among the most psychologically disabled of all cancer groups. Patients with stage IV non–small cell lung cancer (NSCLC) were studied to test the hypothesis that trajectories of depression and/or anxiety symptoms after diagnosis would show an adverse relationship with survival, beyond relevant controls. Methods: Patients with stage IV NSCLC (n = 157) were enrolled (ClinicalTrials.gov Identifier: NCT03199651) at diagnosis and completed validated measures for depressive symptoms (Patient Health Questionnaire-9) and anxiety symptoms (Generalized Anxiety Disorder-7). Patients were reassessed every 1 to 2 months through 24 months (16 assessments; 80% average completion rate) and survival monitored. Joint statistical models provided simultaneous modeling of longitudinal (psychological) and time-to-event (survival) processes. Control variables were age, sex, marital status, education, smoking status, cancer type, and treatment received. Results: Depression and anxiety symptoms significantly decreased with time since diagnosis. The 2-year trajectory of depressive symptoms was significantly associated with cancer survival after adjustment for covariates (hazard ratio = 1.09 per unit increase in the Patient Health Questionnaire-9, 95% confidence interval = 1.03–1.15, p = .002). Anxiety was marginally significant in the unadjusted (p = .053) but not the adjusted (p = .39) model. Conclusions: For the first time, joint model analyses test the interaction of a longitudinal trajectory of psychological symptoms, assessed from diagnosis to 24 months, and cancer survival. New data show the continuation of depressive and anxiety symptoms through treatment and thereafter. Immunotherapy and targeted therapies have dramatically improved survival for patients with advanced NSCLC; however, novel data suggest their benefit may be constrained by depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depression at diagnosis and throughout the cancer trajectory 16 covaries with lower adherence to treatment and follow-up care, increased inflammation, impaired immunity, and reduced survival.17,18”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depression at diagnosis and throughout the cancer trajectory 16 covaries with lower adherence to treatment and follow-up care, increased inflammation, impaired immunity, and reduced survival.17,18”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Depression at diagnosis and throughout the cancer trajectory 16 covaries with lower adherence to treatment and follow-up care, increased inflammation, impaired immunity, and reduced survival.17,18”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Depression at diagnosis and throughout the cancer trajectory 16 covaries with lower adherence to treatment and follow-up care, increased inflammation, impaired immunity, and reduced survival.17,18”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942 · cited 1×
“A commonality among depression (25,26), lung cancer (27), and immune checkpoint inhibiting therapies (28,29) is their inflammatory-inducing effects (30), occurring in an immune system already vulnerable from smoking (31) and age-related cellular function decline (32,33).”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766 · cited 1×
“A commonality among depression (25,26), lung cancer (27), and immune checkpoint inhibiting therapies (28,29) is their inflammatory-inducing effects (30), occurring in an immune system already vulnerable from smoking (31) and age-related cellular function decline (32,33).”
BackgroundAnxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age
Linden, W., Vodermaier, A., MacKenzie, R., & Greig, D. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.025 · Cited by 1,245
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Do stress-related psychosocial factors contribute to cancer incidence and survival?
Chida, Y., Hamer, M., Wardle, J., & Steptoe, A. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1134 · Cited by 1,072 · cited 3×
“Kaplan-Meyer estimates and Cox models (2,6,7), meta-analyses find that baseline assessments are associated with shortened survival across cancer types (6), including those with depression and lung cancer (n = 4476; hazard ratio [HR] = 1.”
BackgroundMethodA systematic review of reviews on the prevalence of anxiety disorders in adult populations
Remes, O., Brayne, C., van der Linde, R., & Lafortune, L. (2016) · Brain and Behavior · doi:10.1002/brb3.497 · Cited by 802 · cited 1×
“Anxiety has been less studied but tested because of the commonality of anxiety disorders, particularly generalized anxiety disorder (GAD) (9), and its comorbidity with depressive disorders (10).”
Background
Research works printed but not linked: 1
- 2004, Joint modeling of longitudinal and time-to-event data: an overview, Stat Sinica, 14, 809
Cited by
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
Andersen, B. L., Lacchetti, C., Ashing, K., Berek, J. S., Berman, B. S., Bolte, S., Dizon, D. S., Given, B., Nekhlyudov, L., Pirl, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00293 · Cited by 318
Self-citationYao, J., Chen, X., Meng, F., Cao, H., & Shu, X. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.10.002 · Cited by 117
Valentine, T. R., Presley, C. J., Carbone, D. P., Shields, P. G., & Andersen, B. L. (2022) · Health Psychology · doi:10.1037/hea0001192 · Cited by 66
Self-citationUngvari, Z. I., Fekete, M., Buda, A., Lehoczki, A., Fekete, J. T., Varga, P., Ungvari, A., & Győrffy, B. (2025) · GeroScience · doi:10.1007/s11357-025-01676-9 · Cited by 64
Obeng-Gyasi, S., Li, Y., Carson, W. E., Reisinger, S., Presley, C. J., Shields, P. G., Carbone, D. P., Ceppa, D. P., Carlos, R. C., & Andersen, B. L. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.21626 · Cited by 34
“Cutoff values are none or mild (1-7), moderate (8-14), moderate to severe (15-19), and severe (20-27).”
BackgroundSelf-citation
Metadata
- Authors
- Andersen, B. L., McElroy, J. P., Carbone, D. P., Presley, C. J., Smith, R. M., Shields, P. G., & Brock, G. N.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Andersen, Barbara L.
- ORCID
- Venue
- Psychosomatic Medicine
- Published
- 2021-10-11
- Volume
- 84
- Issue
- 2
- Pages
- 215-223
- ISSN
- 0033-3174 (ISSN-L)
- 1534-7796
- PMC
- PMC8831460
- OpenAlex
- W3207142517
- Cited by
- 37
- References
- 39
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 14 · 2023: 9 · 2022: 5 · 2021: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychosomatic Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002733)
- National Institute on Aging (R03AG064374, K76AG074923)
- National Cancer Institute (P30CA016058, K12CA133250)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- non-small cell lung cancer, depression, anxiety, cancer survival, stage IV lung cancer, joint modeling of longitudinal and survival data, PHQ-9, Generalized Anxiety Disorder-7, advanced cancer
- MeSH terms
- Anxiety, Anxiety Disorders, Carcinoma, Non-Small-Cell Lung, Depression, Humans, Lung Neoplasms, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychological Symptom Trajectories and Non–Small Cell Lung Cancer Survival: A Joint Model Analysis. https://app.cochat.ai/papers/10.1097/psy.0000000000001027
- The paper
- Andersen, B. L., McElroy, J. P., Carbone, D. P., Presley, C. J., Smith, R. M., Shields, P. G., & Brock, G. N. (2022). Psychological Symptom Trajectories and Non–Small Cell Lung Cancer Survival: A Joint Model Analysis. Psychosomatic Medicine. https://doi.org/10.1097/psy.0000000000001027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.